-
-
Small Molecule Drug Platform
-
Chiral Catalysis Technology
-
Continuous Flow Technology
-
Fluorine Chemistry
-
Enzyme Catalysis
-
Photocatalysis
-
Solid-State Research
显示更多 -
-
Drug Product (DP) Platforms
-
Sustained and Controlled Release
-
Solubility Enhancement
-
Topical Formulation
-
Liquid Formulation
-
Softgels
-
Flow-through cell
显示更多 -
-
Peptide Platform
显示更多 -
Research Team
显示更多
-
Service Platform
Related Services and Solutions
We look forward to working with you and providing you with excellent service.
DP Production Base — Rayhua Zhongshan
Sandoz (China) 's Zhongshan Plant, a DP production base of Sandoz (a division of the Novartis Group) in China, joined Jiuzhou Pharma on March 31, 2023. The site maintains robust quality management systems and provides sophisticated capabilities in solid dosage form and ointment (gel) production, as well as process improvement, technology transfer, and reliable supply.
Floor area:50,000 m2. Existing workshops (China GMP): solid dosage form and ointment (gel); planned workshops: oral solutions, softgels, and anticancer drugs.
Quality management:With robust quality management systems and SOPs, the site obtained certifications/approvals from national, provincial, municipal, and overseas regulatory agencies and passed global quality audits conducted by world-leading pharmaceutical companies.
Management team:The core management team, which hails from world-leading pharmaceutical companies, brings extensive expertise in technology transfer, project management, and quality assurance, as well as experience with China's centralized drug procurement.
Business Collaboration
Innovative Drug CDMO Services